ReviewJournal of thrombosis and thrombolysis2010
Update on heparin: what do we need to know?
Review in Journal of thrombosis and thrombolysis, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Slow versus fast subcutaneous heparin injections for prevention of bruising and site pain intensity.The Cochrane database of systematic reviews · 2021Pooled it
- Pooled it
- Heparin for the prevention of intraventricular haemorrhage in preterm infants.The Cochrane database of systematic reviews · 2016Pooled it
- Study of Modifications Induced by Continued Direct Oral Anticoagulant Therapy during Atrial Fibrillation Ablation Procedures on Standard Hemostasis Parameters.Journal of clinical medicine · 2023Article
- Inhibition of platelet-surface-bound proteins during coagulation under flow II: Antithrombin and heparin.Biophysical journal · 2023Article
- Chemically Modified Biopolymers for the Formation of Biomedical Hydrogels.Chemical reviews · 2021Review
- Individual variation in unfractionated heparin dosing after pediatric cardiac surgery.Scientific reports · 2020Article
- Transfusion characteristics and hemostatic conditions in octogenarians undergoing emergency surgery for acute aortic dissection: a retrospective study.JA clinical reports · 2020Article
- Synthesis, characterization and anticoagulant activity of chitosan derivatives.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2020Article
- The Role of Tinzaparin in Oncology.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis · 2018Review
- Low-molecular-weight sulfonated chitosan as template for anticoagulant nanoparticles.International journal of nanomedicine · 2018Article
- Erratum to: Pharmacology of anticoagulants used in the treatment of venous thromboembolism.Journal of thrombosis and thrombolysis · 2016Article
- Pharmacology of anticoagulants used in the treatment of venous thromboembolism.Journal of thrombosis and thrombolysis · 2016Review
- Reversal of anticoagulant effects in patients with intracerebral hemorrhage.Current neurology and neuroscience reports · 2015Review
- Low anticoagulant heparin blocks thrombin-induced endothelial permeability in a PAR-dependent manner.Vascular pharmacology · 2014Article
- Anticoagulants: A Review of the Pharmacology, Dosing, and Complications.Current emergency and hospital medicine reports · 2013Article
- Obstetrical Management of an Extremely Overweight Pregnant Woman (184 kg bw) with Special Attention on Thromboprophylaxis.Case reports in obstetrics and gynecology · 2013Article
- Tinzaparin and other low-molecular-weight heparins: what is the evidence for differential dependence on renal clearance?Experimental hematology & oncology · 2013Review
- Engineered virus-like nanoparticles reverse heparin anticoagulation more consistently than protamine in plasma from heparin-treated patients.Thrombosis research · 2011Article
- Heterofucans from the brown seaweed Canistrocarpus cervicornis with anticoagulant and antioxidant activities.Marine drugs · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over the last 15 years, there has been a shift from unfractionated heparin to low-molecular-weight heparin or fondaparinux for many indications. Nonetheless, heparin continues to be used and it remains the drug of choice for selected indications and patients. This paper reviews when and how to use heparin and when low-molecular-weight heparin or fondaparinux may be a better choice. The paper also describes some of the new parenteral anticoagulants under development and provides perspective on how the introduction of rapid-acting oral thrombin or factor Xa inhibitors is likely to reduce or eliminate the need for bridging with parenteral anticoagulants.
Indexed as
Identifiers
19882363What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.